Literature DB >> 24365790

ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signatures in multiple myeloma.

W Zhou1, Y Yang1, Z Gu1, H Wang1, J Xia1, X Wu2, X Zhan3, D Levasseur1, Y Zhou1, S Janz4, G Tricot1, J Shi2, F Zhan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24365790      PMCID： PMC4018236          DOI： 10.1038/leu.2013.383

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  The molecular classification of multiple myeloma.

Authors:  Fenghuang Zhan; Yongsheng Huang; Simona Colla; James P Stewart; Ichiro Hanamura; Sushil Gupta; Joshua Epstein; Shmuel Yaccoby; Jeffrey Sawyer; Bart Burington; Elias Anaissie; Klaus Hollmig; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

Review 2.  Aldehyde dehydrogenases and cell proliferation.

Authors:  G Muzio; M Maggiora; E Paiuzzi; M Oraldi; R A Canuto
Journal:  Free Radic Biol Med       Date:  2011-12-21       Impact factor: 7.376

Review 3.  Target for cancer therapy: proliferating cells or stem cells.

Authors:  M V Blagosklonny
Journal:  Leukemia       Date:  2006-03       Impact factor: 11.528

4.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

Authors:  John D Shaughnessy; Fenghuang Zhan; Bart E Burington; Yongsheng Huang; Simona Colla; Ichiro Hanamura; James P Stewart; Bob Kordsmeier; Christopher Randolph; David R Williams; Yan Xiao; Hongwei Xu; Joshua Epstein; Elias Anaissie; Somashekar G Krishna; Michele Cottler-Fox; Klaus Hollmig; Abid Mohiuddin; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Jeffrey Sawyer; Yazan Alsayed; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2006-11-14       Impact factor: 22.113

Review 5.  Aldehyde dehydrogenase as a marker for stem cells.

Authors:  Jan S Moreb
Journal:  Curr Stem Cell Res Ther       Date:  2008-12       Impact factor: 3.828

6.  Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.

Authors:  William Matsui; Qiuju Wang; James P Barber; Sarah Brennan; B Douglas Smith; Ivan Borrello; Ian McNiece; Lan Lin; Richard F Ambinder; Craig Peacock; D Neil Watkins; Carol Ann Huff; Richard J Jones
Journal:  Cancer Res       Date:  2008-01-01       Impact factor: 12.701

7.  Regulation of embryonic and induced pluripotency by aurora kinase-p53 signaling.

Authors:  Dung-Fang Lee; Jie Su; Yen-Sin Ang; Xonia Carvajal-Vergara; Sonia Mulero-Navarro; Carlos F Pereira; Julian Gingold; Hung-Liang Wang; Ruiying Zhao; Ana Sevilla; Henia Darr; Andrew J K Williamson; Betty Chang; Xiaohong Niu; Francesca Aguilo; Elsa R Flores; Yuh-Pyng Sher; Mien-Chie Hung; Anthony D Whetton; Bruce D Gelb; Kateri A Moore; Hans-Willem Snoeck; Avi Ma'ayan; Christoph Schaniel; Ihor R Lemischka
Journal:  Cell Stem Cell       Date:  2012-08-03       Impact factor: 24.633

8.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.

Authors:  Christophe Ginestier; Min Hee Hur; Emmanuelle Charafe-Jauffret; Florence Monville; Julie Dutcher; Marty Brown; Jocelyne Jacquemier; Patrice Viens; Celina G Kleer; Suling Liu; Anne Schott; Dan Hayes; Daniel Birnbaum; Max S Wicha; Gabriela Dontu
Journal:  Cell Stem Cell       Date:  2007-11       Impact factor: 24.633

9.  Aldehyde dehydrogenase 1a1 is dispensable for stem cell function in the mouse hematopoietic and nervous systems.

Authors:  Boaz P Levi; Omer H Yilmaz; Gregg Duester; Sean J Morrison
Journal:  Blood       Date:  2008-10-29       Impact factor: 22.113

10.  Thalidomide and hematopoietic-cell transplantation for multiple myeloma.

Authors:  Bart Barlogie; Guido Tricot; Elias Anaissie; John Shaughnessy; Erik Rasmussen; Frits van Rhee; Athanasios Fassas; Maurizio Zangari; Klaus Hollmig; Mauricio Pineda-Roman; Choon Lee; Giampaolo Talamo; Raymond Thertulien; Elias Kiwan; Somashekar Krishna; Michele Fox; John Crowley
Journal:  N Engl J Med       Date:  2006-03-09       Impact factor: 91.245
View more
  35 in total

1.  Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma.

Authors:  Ye Yang; Jumei Shi; Zhimin Gu; Mohamed E Salama; Satyabrata Das; Erik Wendlandt; Hongwei Xu; Junwei Huang; Yi Tao; Mu Hao; Reinaldo Franqui; Dana Levasseur; Siegfried Janz; Guido Tricot; Fenghuang Zhan
Journal:  Cancer Res       Date:  2015-01-14       Impact factor: 12.701

2.  CD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1/CXCR4/AKT signaling pathway.

Authors:  Dan Wu; Xinyi Guo; Jing Su; Ruoying Chen; Dmitriy Berenzon; Martin Guthold; Keith Bonin; Weiling Zhao; Xiaobo Zhou
Journal:  Biochim Biophys Acta       Date:  2014-11-21

3.  BUB1B promotes multiple myeloma cell proliferation through CDC20/CCNB axis.

Authors:  Ye Yang; Chunyan Gu; Chen Luo; Fei Li; Min Wang
Journal:  Med Oncol       Date:  2015-02-20       Impact factor: 3.064

4.  NEDD9 links anaplastic thyroid cancer stemness to chromosomal instability through integrated centrosome asymmetry and DNA sensing regulation.

Authors:  Henry G Yu; Krikor Bijian; Sabrina D da Silva; Jie Su; Gregoire Morand; Alan Spatz; Moulay A Alaoui-Jamali
Journal:  Oncogene       Date:  2022-04-22       Impact factor: 9.867

5.  HIF-1α and rapamycin act as gerosuppressant in multiple myeloma cells upon genotoxic stress.

Authors:  Clémence Coudre; Julien Alani; William Ritchie; Véronique Marsaud; Brigitte Sola; Julie Cahu
Journal:  Cell Cycle       Date:  2016-06-24       Impact factor: 4.534

6.  Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma.

Authors:  Reinaldo Franqui-Machin; Mu Hao; Hua Bai; Zhimin Gu; Xin Zhan; Hasem Habelhah; Yogesh Jethava; Lugui Qiu; Ivana Frech; Guido Tricot; Fenghuang Zhan
Journal:  J Clin Invest       Date:  2018-06-04       Impact factor: 14.808

7.  Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma.

Authors:  Mu Hao; Meirong Zang; Erik Wendlandt; Yan Xu; Gang An; Dasen Gong; Fei Li; Fang Qi; Yanru Zhang; Ye Yang; Fenghuang Zhan; Lugui Qiu
Journal:  Int J Cancer       Date:  2014-09-19       Impact factor: 7.396

Review 8.  Development of small molecular compounds targeting cancer stem cells.

Authors:  Jae-Hyun Park; Suyoun Chung; Yo Matsuo; Yusuke Nakamura
Journal:  Medchemcomm       Date:  2016-11-11       Impact factor: 3.597

9.  miR-19a-3p Functions as an Oncogene by Regulating FBXO32 Expression in Multiple Myeloma.

Authors:  Ying Li; Song Gao; Wenjing Xue; Yanna Ma; Yuesheng Meng; Dawei Zhang
Journal:  Balkan Med J       Date:  2021-01       Impact factor: 2.021

10.  CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma.

Authors:  Chunyan Gu; Wang Wang; Xiaozhu Tang; Tingting Xu; Yanxin Zhang; Mengjie Guo; Rongfang Wei; Yajun Wang; Artur Jurczyszyn; Siegfried Janz; Meral Beksac; Fenghuang Zhan; Anja Seckinger; Dirk Hose; Jingxuan Pan; Ye Yang
Journal:  Mol Cancer       Date:  2021-06-05       Impact factor: 27.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.